An early first-in-human study is underway for ABBV-706, a SEZ6-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors. The program’s Journal of Clinical Oncology conference publication (ASCO 2024 supplement) outlines the clinical-development stage and indicates ongoing dose and safety evaluation for a neuro-targeting ADC payload strategy.